domingo, 22 de noviembre de 2026

Cancer Drug Approval Standards Face New Scrutiny Nov 20, 2026

https://www.medscape.com/for-you?hpid=7&ecd=mkm_ret_261122_mscpmrk_onc_perspectives_clihub_etid8923416&uac=148436CN&impID=8923416 Cancer drug access decisions increasingly affect oncology practice after trials meet endpoints but before long-term benefit is fully defined. Most evidence here comes from European and North American policy discussions, yet the approval and access questions map directly to United States cancer care and formulary use.

No hay comentarios:

Publicar un comentario